RENAISSANCE Study: A Phase 2a, Multicenter, Open Label Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
Latest Information Update: 27 May 2024
At a glance
- Drugs Huperzine A (Primary)
- Indications Epilepsy; Seizures
- Focus Adverse reactions
- Acronyms RENAISSANCE Study
- Sponsors Supernus Pharmaceuticals
- 23 May 2024 Interim results (n=41 as of May 1, 2024) were presented in a Supernus Pharmaceuticals Media Release.
- 09 May 2024 According to a Supernus Pharmaceuticals media release, Company will hold a webcast and conference call on Thursday, May 23, 2024 to review interim data from this study.
- 27 Feb 2024 According to a Supernus Pharmaceuticals media release, company expects to report interim results from approximately one-half of the targeted randomized patients in May 2024, and topline results for the full study in the second half of 2024.